Treating paediatric community-acquired pneumonia in the era of antimicrobial resistance.

Abstract

UNLABELLED:

Increasing levels of paediatric community-acquired pneumonia (CAP), caused by drug-resistant bacteria and antimicrobial resistance, vary with age and countries and, in some cases, serotypes. When empirical first-line treatment administration fails, paediatricians should consider second-line treatments based on the prevalence of local resistance. A more judicious use of antimicrobial agents is also required.

CONCLUSION:

Knowledge of local epidemiology and an appropriate use of antimicrobial drugs are necessary to treat CAP in this era of antimicrobial resistance.

• Authors: L Galli, C Montagnani, E Chiappini, M de Martino
• Journal: Acta paediatrica (Oslo, Norway : 1992) (Acta Paediatr) Vol. 102 Issue 465 Pg. 25-33 (Dec 2013) ISSN: 1651-2227 [Electronic] Norway
• PMID: 24330270 (Publication Type: Journal Article, Review)
• Copyright: ©2013 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.

Chemical References

• Anti-Bacterial Agents

Topics

• Anti-Bacterial Agents (therapeutic use)
• Child
• Community-Acquired Infections (drug therapy, microbiology)
• Drug Resistance, Bacterial
• Humans
• Methicillin-Resistant Staphylococcus aureus
• Microbial Sensitivity Tests
• Mycoplasma pneumoniae
• Pneumonia, Bacterial (drug therapy, microbiology)
• Streptococcus pneumoniae